Re:flux Glossary

We love talking about science and created this guide to help you understand all the terminology. You can search, scroll, or explore at your own pace. Still have a question? Send us a message, and we’ll get back to you.

Pharmaceutical / Medical Terms

5-HT4 (Serotonin) Receptors

The "gut's happy buttons" - these receptors get your digestive system moving when activated (5-HT4 = serotonin's fourth cousin, twice removed)

A subtype of serotonin receptor in the gut that promotes movement through the digestive tract. Activation improves gastric motility and helps reduce reflux by enhancing coordinated peristaltic movements and gastric emptying. (1,2)

Acetylcholine (ACh)

Your body's "squeeze signal" - tells muscles when to contract and hold tight (sounds like "acid-choline" but it's actually the good guy)

A neurotransmitter essential for muscle contraction. In digestion, it strengthens the lower esophageal sphincter (LES), preventing acid from rising into the esophagus. ACh also stimulates gastric motility and coordinated digestive function. (3,4)

Atrophic Gastritis

When your stomach lining becomes "paper thin" - often from long-term acid suppression

A condition where the stomach lining becomes thin, inflamed, and loses its acid-producing cells. Commonly develops after prolonged PPI use, leading to reduced acid production, vitamin B12 deficiency, and increased infection risk. Can progress to precancerous changes. (62)

Bile Reflux

The "bitter backup" - when yellow digestive juice flows the wrong way (bile = that gross yellow stuff you throw up when there's nothing left)

The backward flow of bile from the duodenum into the stomach and potentially the esophagus. Unlike acid reflux, bile reflux can cause symptoms even in non-acidic conditions and is often overlooked in reflux management. (5)

Deep Vein Thrombosis (DVT)

Dangerous blood clots in deep veins - a serious risk with long-term PPI use

Formation of blood clots in deep veins, typically in the legs. Studies show increased DVT risk with prolonged PPI therapy, possibly due to effects on platelet function and endothelial dysfunction. Can lead to life-threatening pulmonary embolism. (63)

Dementia

Memory loss and brain fog - studies link this to long-term PPI use

Progressive cognitive decline affecting memory, thinking, and behavior. Multiple studies demonstrate 20-50% increased dementia risk with chronic PPI use, possibly due to vitamin B12 deficiency, altered brain pH, and accumulation of amyloid plaques. (64,65)

Dyspepsia

Fancy word for "my stomach feels awful" - the umbrella term for tummy troubles (doctors love making "I feel crappy" sound important)

A clinical term for indigestion characterized by upper abdominal pain, bloating, early satiety, and discomfort. Often associated with reflux and gastroparesis, representing a complex of symptoms rather than a single disease. (6)

Esophageal Clearance

Your throat's "self-cleaning cycle" - how your body washes away the burn

The body's natural ability to clear refluxed material from the esophagus through coordinated peristaltic waves and saliva production. Impaired clearance prolongs acid contact time and increases tissue damage. (7)

GABA / GABAergic

Your brain's "chill out" system - affects both mood and digestion

Gamma-aminobutyric acid, the brain's primary inhibitory neurotransmitter that promotes calm and relaxation. GABAergic pathways influence gastric motility, stress response, and gut-brain communication. Dysfunction contributes to both anxiety and digestive disorders. (66)

Gastrectomy

Surgical removal of stomach - creates permanent digestive challenges

Partial or complete surgical removal of the stomach, typically for cancer treatment. Results in permanent alterations to acid production, vitamin B12 absorption, and gastric motility. Patients often develop chronic reflux and nutritional deficiencies. (67)

Gastric Motility

Your stomach's "mixing and moving dance" - how food travels through your system

The muscular action of the stomach and intestines that moves food through the digestive tract. Impaired motility is a key contributor to reflux. Prokinetic agents that enhance this function are essential for addressing root causes of GERD. (8,9)

Gastrin

The "acid alarm" hormone - tells your stomach to start making digestive juice (gastrin sounds like "gas-trin" but it's about acid, not gas)

A hormone produced by G cells in the stomach antrum that stimulates hydrochloric acid secretion by parietal cells. Elevated gastrin levels can contribute to hyperacidity and reflux symptoms. (10)

Gastroesophageal Junction

The "critical crossroads" - where your food tube meets your stomach (not to be confused with your windpipe - that's a different tube!)

The anatomical area where the esophagus meets the stomach, including the lower esophageal sphincter. This critical zone is where reflux episodes originate and where protective mechanisms must function properly. (11)

Gastroesophageal Reflux Disease (GERD)

The "chronic fire in your chest" - when heartburn becomes a regular unwelcome guest

A chronic digestive disorder where stomach contents regularly reflux into the esophagus, causing symptoms like heartburn and regurgitation at least twice weekly, or complications such as esophagitis. (12)

Ghrelin

The "hunger hormone" - your stomach's way of saying "feed me!" (sounds like "gremlin" for a reason)

A hormone produced primarily in the stomach that stimulates appetite and affects gastric motility. Ghrelin levels influence digestive timing and may impact reflux susceptibility. (13)

Heartburn

The "chest fire" - street name for acid reflux that feels like your heart is burning (spoiler: your heart is fine, it's your food tube)

The burning sensation in the chest caused by stomach acid irritating the esophageal lining. The primary symptom of gastroesophageal reflux, often accompanied by regurgitation. (14)

Helicobacter pylori

The "stomach spiral troublemaker" - a bacteria that can mess with your acid levels (shaped like a corkscrew, acts like one too)

A spiral-shaped bacteria that can colonize the stomach lining, affecting acid production and gastric health. H. pylori infection is associated with both increased and decreased acid production, depending on infection location. (15)

Hiatal Hernia

When your stomach "pops up" through your diaphragm - imagine your stomach trying to escape through your breathing muscle

A structural condition where part of the stomach protrudes through the diaphragmatic opening into the chest cavity. Present in up to 95% of GERD patients and contributes to LES dysfunction. (16)

Histamine Receptors (H2)

The "acid factory switches" - turn these off and you make less stomach acid

Receptors in the stomach lining that stimulate acid production. Targeted by both conventional H2 blockers and natural acid regulators. H2 receptor antagonists reduce acid secretion by blocking histamine binding. (17)

Hydrochloric Acid (HCl)

Your stomach's "digestive firepower" - the acid that breaks down your food (same stuff that can dissolve metal, but don't worry)

The primary component of stomach acid, crucial for digestion and killing pathogens. Both excessive and insufficient levels can cause discomfort. HCl is produced by parietal cells and is essential for protein digestion and mineral absorption. (18,19)

Intrinsic Factor

The "B12 taxi" - a stomach protein that PPIs can destroy

A glycoprotein produced by parietal cells essential for vitamin B12 absorption in the small intestine. PPI therapy reduces intrinsic factor production, leading to B12 deficiency, anemia, and neurological complications over time. (68)

Lower Esophageal Sphincter (LES)

The "front gate" of your food tube — but it's not the only one on duty.

You’ve got more than just a top and bottom valve — your digestive tract is a series of gates. The LES is a major one, but reflux happens when multiple gates misfire.

A muscular valve at the junction of the esophagus and stomach that plays a primary role in preventing gastroesophageal reflux. While often called "the" sphincter, it's one of several involved in coordinated digestive flow, including the upper esophageal sphincter and pyloric sphincter. LES dysfunction, along with poor motility or hiatal hernia, contributes to reflux by allowing gastric contents to backflow into the esophagus. Tone and function are modulated by neurotransmitters like acetylcholine and affected by dietary, hormonal, and structural factors. (20,21)

Motilin Receptor

The "get things moving" button - helps your digestive system stay active (motilin = motivation for your intestines)

A receptor that helps initiate muscle contractions in the stomach and intestines. Activating motilin receptors enhances motility and digestive flow, providing prokinetic effects that prevent food stagnation and reduce reflux risk. (22)

Parietal Cells

The "acid-making factories" in your stomach - where PPIs do their damage (parietal = "wall cells" because they line your stomach wall)

Cells in the stomach lining that produce hydrochloric acid (HCl). These are the primary target of proton pump inhibitors (PPIs). Parietal cells contain the H+/K+ ATPase enzyme that PPIs permanently disable. (23,24)

Pepsin

The "protein scissors" - an enzyme that can damage your throat even without acid (think of it as molecular Pac-Man eating your tissues)

A protein-digesting enzyme produced in the stomach that remains active even in weakly acidic or alkaline conditions. Pepsin can cause esophageal tissue damage independent of acid levels and is activated from pepsinogen by gastric acid. (25)

Peristalsis

The "wave motion" that moves food through your body - like squeezing toothpaste, but in reverse and much more coordinated

Coordinated wave-like muscle contractions that propel food and liquids through the digestive tract. Essential for both preventing reflux and clearing refluxed material from the esophagus. (26)

Prostaglandins

Your body's "healing helpers" - natural compounds that protect and repair (nothing to do with your prostate, despite the name)

Lipid compounds with hormone-like effects. In the gut, they reduce inflammation, promote healing, and provide gastroprotective effects that protect the mucosal lining from acid, pepsin, and bile damage. (27)

Proton Pump Inhibitors (PPIs)

The "acid shut-off switch" - powerful drugs that turn off your stomach's acid production

Pharmaceutical drugs that permanently block acid production by disabling enzymes in parietal cells. See Conventional Treatments section for detailed clinical information. (28,29)

Regurgitation

The "bitter backup" - when stomach contents come back up without warning (not vomiting, just an unwelcome surprise)

The effortless return of stomach contents to the mouth, often described as a sour or bitter taste. A common symptom of GERD that occurs without the nausea associated with vomiting. (30)

SIBO (Small Intestinal Bacterial Overgrowth)

When "bad bugs" take over your small intestine - often caused by low stomach acid (SIBO rhymes with "bye-bo" which is what you want to say to it)

A condition where excessive bacteria grow in the small intestine, often linked to low stomach acid or poor motility. Associated with bloating, reflux, and food sensitivities. SIBO is more common in patients taking PPIs long-term. (31,32)

Squamous Epithelium

The "wallpaper" lining your esophagus - gets damaged by acid exposure

The flat, protective cell layer lining the esophagus. Unlike stomach tissue, squamous epithelium lacks acid resistance and becomes inflamed, ulcerated, or precancerous when repeatedly exposed to gastric acid and pepsin. (69)

Substance P

The "pain messenger" - sends signals that make your esophagus extra sensitive (P stands for Pain, because scientists are sometimes that simple)

A neuropeptide involved in pain transmission and inflammatory responses. Elevated substance P levels in the esophagus are associated with increased sensitivity and inflammation in GERD patients. (33)

Tachyphylaxis

When drugs become "tired" - your body gets used to them and they stop working

Rapid development of tolerance to a medication, causing diminished therapeutic response despite continued use. Common with H2 blockers and some prokinetic agents, requiring dose escalation or treatment changes to maintain effectiveness. (70)

Tardive Dyskinesia

Uncontrollable muscle movements - a devastating side effect of some reflux drugs

Irreversible movement disorder characterized by repetitive, involuntary muscle movements, particularly of the face and tongue. Associated with long-term use of prokinetic medications like metoclopramide (Reglan). Can be permanent even after stopping the drug. (71)

Transient LES Relaxations (TLESRs)

When your "valve malfunctions" - inappropriate relaxations that cause most reflux (TLESRs = "Totally Lousy Esophageal Sphincter Relaxations")

Brief, inappropriate relaxations of the lower esophageal sphincter that occur independent of swallowing. TLESRs are the primary mechanism behind most

Vagus Nerve

The "master controller" – your body's main nerve that controls digestion (Vegas nerve would be way more fun, but alas...)

The longest cranial nerve that controls parasympathetic functions including gastric acid secretion, LES tone, and gastric motility. Vagal dysfunction can contribute to both reflux and gastroparesis. (35)

Medical / Scientific Concepts

Bioavailability

How much your body can actually absorb and use - not all supplements are equal.

The fraction of an administered substance that reaches systemic circulation and is available for biological activity. Affected by factors including formulation, gastric pH, food interactions, and individual metabolism. Critical for supplement efficacy. (72)

Breakthrough Dosing

"Emergency backup" - taking extra when symptoms flare up (like calling in reinforcements when the battle gets tough).

An additional dose of a supplement or medication taken during acute symptom flare-ups, despite ongoing treatment. This approach allows for individualized symptom management while maintaining baseline therapy.

CYP450 / Liver Enzymes

Your liver's "processing plant" - how your body breaks down drugs and supplements.

Cytochrome P450 enzymes are responsible for metabolizing most medications and many nutrients. PPI therapy can alter CYP450 activity, affecting drug interactions and metabolism of other substances. Individual genetic variations influence enzyme activity. (73)

DRD2, SCF, c-kit

The "cellular communication network" - how your gut cells talk to each other.

Cellular signaling pathways involved in gastrointestinal regulation, motility, and stem cell function. Mostly relevant in clinical or research settings. These pathways are modulated by certain herbal compounds like Atractylodes macrocephala. (36)

Dysbiosis

When your "gut garden" goes bad - imbalanced bacteria causing problems (dys = bad, biosis = life).

An imbalance in the gut microbiome characterized by reduced beneficial bacteria and overgrowth of potentially harmful microorganisms. Often associated with SIBO, inflammation, and altered gut barrier function. (37)

Echo Chamber

When supplement marketing just repeats claims without real proof.

A phenomenon where marketing claims are repeatedly cited without original scientific validation, creating a false impression of evidence. Common in the supplement industry when testimonials and theoretical benefits are presented as established facts.

FDA Approval Process / Black Box Warnings

The government's safety testing system and their most serious drug warnings.

Rigorous evaluation process requiring extensive safety and efficacy data before drug approval. Black Box warnings represent the FDA's strongest safety warning for medications with serious or life-threatening risks. (74)

Functional Medicine

Healthcare detective work - finding and fixing root causes instead of just treating symptoms.

Medical approach focusing on underlying causes, personalized treatment, nutrition, lifestyle, and biochemical individuality. (75)

GRAS (Generally Recognized As Safe)

FDA's stamp of approval for food ingredients - "this won't hurt you."

FDA designation for substances considered safe based on scientific evidence or long history of safe use in food. GRAS status allows ingredients to be marketed without pre-market approval. (76)

Gut-Brain Axis

The "stomach-brain highway" - how your gut and brain constantly chat.

Bidirectional communication between the GI tract and central nervous system involving neural, hormonal, and immune signaling. Disruption affects digestion and symptom perception. (38)

Phase IV (Post-Market Surveillance)

Ongoing safety monitoring after drugs hit the market - real-world testing.

Identifies rare adverse effects, long-term complications, and drug interactions not detected in pre-approval trials. Many PPI risks were discovered in Phase IV studies. (77)

PPI Weaning / Tapering

The art of safely "breaking up" with acid blockers - going slow prevents rebound.

Systematic reduction of PPI dosage over time to minimize rebound acid hypersecretion, usually over 2-8 weeks. Often combined with supportive therapies. (78)

Proof of Concept

Early evidence that an idea might work - the "let's see what happens" stage.

Preliminary demonstration showing biological plausibility before larger clinical trials.

Rebound Hyperacidity

The "acid revenge" - when your stomach overproduces acid after stopping PPIs.

A spike in acid production after discontinuing acid reducers. Causes worsened symptoms and medication dependence. Managed by gradual weaning. (39)

Nutritional / Herbal Compounds

Atractylodes Macrocephala (Bai Zhu)

The "stomach soother" – ancient Chinese herb that calms digestion.

Source: Atractylodes macrocephala. Compound Type: Traditional Chinese herbal root. Traditionally used to support digestion, reduce inflammation, and gently regulate stomach acid. Also known to promote gastric motility via modulation of DRD2, SCF, and c-kit pathways. Exhibits carminative properties that help relieve gas and bloating while providing gastroprotective effects for mucosal healing. (36,40)

Carminative

"Gas busters" – herbs that help you get rid of uncomfortable gas and bloating.

A classification for herbs and compounds that relieve gas, bloating, and digestive discomfort by promoting the expulsion of gas from the GI tract. Many traditional digestive herbs exhibit carminative properties, including dandelion root and Atractylodes macrocephala. (41)

Dandelion Root

Source: Taraxacum officinale.

Compound Type: Herbal root (bitter tonic). Supports liver function, bile production, and digestion. Used traditionally to reduce bloating and stimulate gastric secretions. Acts as a carminative agent that helps expel gas from the GI tract while providing prokinetic effects that enhance digestive motility. (42,43)

Demulcent

"Nature's bandage" – creates a protective coating over irritated tissues.

A substance that forms a protective, soothing coating on irritated mucous membranes. Demulcent herbs create a barrier that shields damaged tissue from further irritation while promoting healing. Noni fruit demonstrates demulcent properties through its bioactive compounds. (44)

Flavonoids

The "plant protectors" – colorful compounds that fight inflammation and heal.

A subclass of polyphenols found abundantly in fruits, vegetables, and herbs. Flavonoids like hesperidin demonstrate anti-inflammatory, antioxidant, and gastroprotective properties relevant to reflux management. These compounds modulate multiple cellular pathways involved in digestive health. (45)

Gastroprotective

"Stomach armor" – compounds that shield and heal your digestive lining.

Describes compounds or mechanisms that protect the gastric and esophageal mucosa from damage caused by acid, pepsin, bile, or inflammatory mediators. Goes beyond simple acid suppression to promote tissue healing through enhanced prostaglandin production and mucosal barrier function. (46)

Hesperidin

Source: Citrus aurantium (bitter orange), Citrus sinensis (sweet orange).

Compound Type: Citrus flavonoid glycoside. A flavonoid that modulates the gut-brain axis, enhances motility via serotonin signaling, and offers anti-inflammatory protection for the gastric mucosa. Demonstrates prokinetic effects by improving gastric emptying and gastroprotective properties that support mucosal healing. (47,48)

Mucilage

Nature's "slime coat" – slippery plant substances that soothe and protect.

Gelatinous polysaccharide substance produced by plants that forms protective, lubricating films on mucous membranes. Acts as a demulcent, providing mechanical protection against acid and irritants while promoting tissue healing. Found in aloe, marshmallow root, and other therapeutic plants. (79)

Noni Fruit

Source: Morinda citrifolia.

Compound Type: Tropical fruit (adaptogen and anti-inflammatory). Shown in clinical and preclinical studies to soothe esophageal inflammation, protect mucosal tissue, and enhance immune activity. Rich in polyphenols and acts as a demulcent that forms a protective coating on irritated mucous membranes while providing gastroprotective effects through its bioactive compound scopoletin. (49,50)

Polyphenols

"Nature's medicine cabinet" – powerful plant compounds that heal and protect.

Source: Naturally found in plants including fruits, vegetables, herbs, and bark (e.g., citrus, noni, dandelion, Atractylodes). Compound Type: Antioxidant-rich micronutrient family. Polyphenols, including flavonoids like hesperidin, are known to regulate inflammation, modulate the microbiome, and support gut-brain communication. In Re:flux, polyphenols work synergistically to strengthen the LES, improve motility through prokinetic mechanisms, provide gastroprotective effects, and reduce acid damage — without the long-term risks of PPIs. Many polyphenol-rich herbs also exhibit carminative and demulcent properties that support comprehensive digestive healing. (45,47,49,51,52)

Prokinetic

"Digestive traffic directors" – compounds that keep food moving in the right direction.

Refers to agents that enhance gastrointestinal motility by stimulating muscle contractions and coordinated movement. Prokinetic effects help prevent reflux by improving gastric emptying and esophageal clearance. Natural prokinetic compounds work through serotonin and motilin pathways. (53)

Terpenes

The "essential oils" of plants – aromatic compounds with healing properties.

Diverse class of organic compounds responsible for plant aromas and many therapeutic effects. Contribute to anti-inflammatory, gastroprotective, and motility-enhancing properties of medicinal plants. Work synergistically with other plant compounds to enhance bioavailability and efficacy. (80)

Conventional Treatments for Reflux

Alginate

“Seaweed shields” – creates a floating foam barrier to block acid (literally kelp helping your gut, who knew?).

A natural polysaccharide derived from seaweed that forms a protective foam barrier on top of stomach contents. Alginates create a physical barrier that floats on gastric contents, helping prevent reflux episodes. Commonly found in over-the-counter reflux medications like Gaviscon. Works mechanically rather than chemically, providing temporary symptom relief without affecting acid production. (54)

Antacids

“Acid neutralizers” – the quick fix that fights fire with chalk (literally calcium carbonate = fancy chalk).

Over-the-counter medications that neutralize existing stomach acid through alkaline compounds like calcium carbonate, magnesium hydroxide, or aluminum hydroxide. Common brands include Tums, Rolaids, and Mylanta. Provide rapid but short-term symptom relief by chemically neutralizing acid rather than reducing acid production. Do not address underlying causes of reflux. (55)

H2 Receptor Antagonists (H2 Blockers)

“Acid dimmers” – turn down your stomach’s acid production (H2 as in histamine-2, not the explosive gas).

Medications that reduce stomach acid production by blocking histamine H2 receptors on parietal cells. Common examples include ranitidine (Zantac), famotidine (Pepcid), and cimetidine (Tagamet). Less potent than PPIs but with fewer long-term side effects. Provide moderate acid suppression and are often used for mild to moderate reflux symptoms. (56,57)

Prokinetic Medications

“Digestive motivators” – prescription drugs that force your gut to move (like a drill sergeant for your intestines, but with more side effects).

Prescription drugs that enhance gastric motility and strengthen lower esophageal sphincter function. Examples include metoclopramide (Reglan) and domperidone. While these address some root causes like delayed gastric emptying, they carry significant side effects including tardive dyskinesia and neurological complications. Limited long-term use due to safety concerns. (58,59)

Proton Pump Inhibitors (PPIs)

“Acid assassins” – the heavy hitters that shut down your stomach’s acid factories.

Pharmaceutical drugs that permanently block acid production by disabling enzymes in parietal cells. Often used to manage symptoms, but they do not address root causes and carry long-term risks including dementia, osteoporosis, and nutrient deficiencies. Examples include omeprazole (Prilosec), esomeprazole (Nexium), and pantoprazole (Protonix). The most potent acid suppressors but create dependency and rebound effects. (28,29)

Protocols and Supplement Use

Emergency Protocol

“Fire drill for your gut” – what to do when reflux hits hard (because sometimes your stomach throws a surprise party and you're not invited).

Steps taken to manage severe or acute acid reflux symptoms.

Initial Treatment Phase

“Boot camp for your stomach” – higher doses to get results started.

The first stage of treatment with a higher dose to establish efficacy.

Maintenance Phase

“Cruise control” – the ongoing dose that keeps you feeling good.

The ongoing dosage used after initial treatment to maintain results.

PPI Weaning Protocol

“Breaking up with acid blockers” – how to safely stop PPIs without the rebound (it's complicated, like most breakups).

A structured approach to gradually reduce and stop the use of PPIs under supervision.

Complete Reference List

  1. Heanue TA, Pachnis V. Serotonin signaling in the gastrointestinal tract. Wiley Interdiscip Rev Dev Biol. 2023;12(4):e292.  
  2. Gershon MD. 5-Hydroxytryptamine (serotonin) in the gastrointestinal tract. Curr Opin Endocrinol Diabetes Obes. 2013;20(1):14-21.  
  3. Li Y, Xu B, Li Z. The role of cholinergic pathways in gastrointestinal motility. Front Pharmacol. 2015;6:93.  
  4. Furness JB. The enteric nervous system and neurogastroenterology. Nat Rev Gastroenterol Hepatol. 2012;9(5):286-294.  
  5. Menges M, Müller M, Zeitz M. Increased acid and bile reflux in Barrett's esophagus compared to reflux esophagitis, and effect of proton pump inhibitor therapy. Am J Gastroenterol. 2001;96(2):331-337.  
  6. Talley NJ, Ford AC. Functional dyspepsia. N Engl J Med. 2015;373(19):1853-1863.  
  7. Kahrilas PJ, Dodds WJ, Hogan WJ, Kern M, Arndorfer RC, Reece A. Esophageal peristaltic dysfunction in peptic esophagitis. Gastroenterology. 1986;91(4):897-904.  
  8. Camilleri M. Gastric motility and its disorders. Gastroenterol Clin North Am. 2015;44(1):45-57. 
  9. Camilleri M, Parkman HP, Shafi MA, Abell TL, Gerson L. Clinical guideline: management of gastroparesis. Am J Gastroenterol. 2013;108(1):18-37.  
  10. Schubert ML, Peura DA. Control of gastric acid secretion in health and disease. Gastroenterology. 2008;134(7):1842-1860.  
  11. Mittal RK, Balaban DH. The esophagogastric junction. N Engl J Med. 1997;336(13):924-932.  
  12. Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101(8):1900-1920.  
  13. Levin F, Edholm T, Schmidt PT, Grybäck P, Jacobsson H, Degerblad M, et al. Ghrelin stimulates gastric emptying and hunger in normal-weight humans. J Clin Endocrinol Metab. 2006;91(9):3296-3302.  
  14. Fass R, Achem SR. Noncardiac chest pain: epidemiology, natural course and pathogenesis. J Neurogastroenterol Motil. 2011;17(2):110-123.  
  15. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med. 2002;347(15):1175-1186.  
  16. Kahrilas PJ, Kim HC, Pandolfino JE. Approaches to the diagnosis and grading of hiatal hernia. Best Pract Res Clin Gastroenterol. 2008;22(4):601-616.  
  17. Sachs G, Shin JM, Howden CW. The clinical pharmacology of proton pump inhibitors. Aliment Pharmacol Ther. 2006;23 Suppl 2:2-8.  
  18. Waldum HL, Sagatun L, Mjones P. Gastric acid secretion: regulation and role in Helicobacter pylori-associated disease. Scand J Gastroenterol. 2015;50(8):933-939.  
  19. Martinsen TC, Bergh K, Waldum HL. The role of pepsin and other proteolytic enzymes in the development of esophageal mucosal injury. Curr Opin Gastroenterol. 2005;21(6):626-632.  
  20. Goyal RK, Chaudhury A. Physiology of the lower esophageal sphincter. Am J Gastroenterol. 2008;103(3):750-760.  
  21. Fass R, Ofman JJ. Gastroesophageal reflux disease--should we adopt a new conceptual framework? Am J Gastroenterol. 2002;97(8):1901-1909.  
  22. Itoh Z. Motilin and clinical application. Peptides. 1997;18(4):593-608.  
  23. Helander HF, Fändriks L. Surface area of the digestive tract—revisited. Scand J Gastroenterol. 2014;49(6):681-689.  
  24. Metz DC. Potential uses of proton pump inhibitors in Helicobacter pylori-associated diseases. Am J Med. 1999;107(5A):35S-42S.  
  25. Piper DW, Fenton BH. pH stability and activity curves of pepsin with special reference to their clinical importance. Gut. 1965;6(5):506-508.  
  26. Goyal RK, Hirano I. The enteric nervous system. N Engl J Med. 1996;334(17):1106-1115.  
  27. Wallace JL. Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn't the stomach digest itself? Physiol Rev. 2008;88(4):1547-1565.  
  28. Forgacs I, Loganayagam A. Overprescribing proton pump inhibitors. BMJ. 2008;336(7634):2-3.  
  29. Wolfe MM, Sachs G. Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress ulcer prophylaxis. Gastroenterology. 2000;118(2 Suppl 1):S9-S31.  
  30. Dent J, El-Serag HB, Wallander MA, Johansson S. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2005;54(5):710-717.  
  31. Lombardo L, Foti M, Ruggia O, Chiecchio A. Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. Clin Gastroenterol Hepatol. 2010;8(6):504-508.  
  32. DiBaise JK, Young RJ, Vanderhoof JA. Small intestinal bacterial overgrowth: nutritional implications. Nutr Clin Pract. 2006;21(5):515-524.  
  33. Björkman DJ, Liebregts T, Fungbrant J, Claesson BH. Substance P in esophageal inflammation and its role in gastroesophageal reflux disease. Curr Gastroenterol Rep. 2007;9(3):200-207.  
  34. Dent J, Dodds WJ, Friedman RH, Sekiguchi T, Hogan WJ, Arndorfer RC, et al. Mechanism of gastroesophageal reflux in recumbent asymptomatic human subjects. J Clin Invest. 1980;65(2):256-267.  
  35. Travagli RA, Hermann GE, Browning KN, Rogers RC. Brainstem circuits regulating gastric function. Annu Rev Physiol. 2006;68:279-305.  
  36. Fan J, Yu J, Zhang L. Rhizoma Atractylodis Macrocephalae: assessing the influence of different processing methods. Front Pharmacol. 2023;14:1236656.  
  37. Huttenhower C, Gevers D, Knight R, Abubucker S, Badger JH, Chinwalla AT, et al. Structure, function and diversity of the healthy human microbiome. Nature. 2012;486(7402):207-214.  
  38. Cryan JF, O'Riordan KJ, Cowan CSM, Sandhu KV, Bastiaanssen TFS, Boehme M, et al. The microbiota-gut-brain axis. Physiol Rev. 2019;99(4):1877-2013.  
  39. Reimer C, Søndergaard B, Hilsted L, Bytzer P. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology. 2009;137(1):80-87.  
  40. Liu J, Chen L, Fan C, Zhu L, Tang S, Cao H, et al. Qualitative and quantitative analysis of major constituents of Paeoniae Radix Alba and Paeoniae Radix Rubra by HPLC-DAD-Q-TOF-MS/MS. J Pharm Biomed Anal. 2018;148:12-21.  
  41. Mahady GB, Pendland SL, Yun G, Lu ZZ. Turmeric (Curcuma longa) and curcumin inhibit the growth of Helicobacter pylori, a group 1 carcinogen. Anticancer Res. 2002;22(6C):4179-4181.  
  42. Schütz K, Carle R, Schieber A. Taraxacum—a review on its phytochemical and pharmacological profile. J Ethnopharmacol. 2006;107(3):313-323.  
  43. González-Castejón M, Visioli F, Rodriguez-Casado A. Diverse biological activities of dandelion. Nutr Rev. 2012;70(9):534-547.  
  44. Bone K, Mills S. Principles and Practice of Phytotherapy. 2nd ed. Edinburgh: Churchill Livingstone; 2013.  
  45. Panche AN, Diwan AD, Chandra SR. Flavonoids: an overview. J Nutr Sci. 2016;5:e47.  
  46. Brzozowski T, Konturek PC, Konturek SJ, Brzozowska I, Pawlik T. Role of prostaglandins in gastroprotection and gastric adaptation. J Physiol Pharmacol. 2005;56 Suppl 5:33-55.  
  47. Roohbakhsh A, Parhiz H, Soltani F, Rezaee R, Iranshahi M. Molecular mechanisms behind the biological effects of hesperidin and hesperetin for the prevention of cancer and cardiovascular diseases. Life Sci. 2015;124:64-74.  
  48. Elavarasan J, Velusamy P, Ganesan T, Ramakrishnan SK, Rajasekaran D, Periandavan K. Hesperidin-mediated expression of Nrf2 and upregulation of antioxidant status in senescent rat heart. J Pharm Pharmacol. 2012;64(10):1472-1482.  
  49. Wang MY, West BJ, Jensen CJ, Nowicki D, Su C, Palu AK, et al. Morinda citrifolia (Noni): a literature review and recent advances in Noni research. Acta Pharmacol Sin. 2002;23(12):1127-1141.  
  50. Akihisa T, Matsumoto K, Tokuda H, Yasukawa K, Seino K, Nakamoto K, et al. Anti-inflammatory and potential cancer chemopreventive constituents of the fruits of Morinda citrifolia (Noni). J Nat Prod. 2007;70(5):754-757.  
  51. Brown K, Scott-Hoy B. Efficacy of a Quebracho, Conker Tree, and M. balsamea Willd. blended extract in a randomized study in patients with irritable bowel syndrome with constipation. J Gastroenterol Hepatol Res. 2015;4(9):1706-1712.  
  52. Brown K, Scott-Hoy B. Botanical blend improves symptoms of irritable bowel syndrome with constipation: Results from a real-world observational study. World J Gastrointest Pharmacol Ther. 2016;7(3):397-405.  
  53. Martin CR, Osadchiy V, Mayer EA. The gastroprotective role of dietary polyphenols. Nutrients. 2021;13(8):2741.  
  54. Strugala V, Bassin J, Swales VS, Lindow SW, Dettmar PW, Thomas EC. Assessment of the safety and efficacy of a raft-forming alginate reflux suppressant (liquid Gaviscon) for the treatment of heartburn during pregnancy. ISRN Obstet Gynecol. 2012;2012:481870.  
  55. Maton PN, Burton ME. Antacids revisited: a review of their clinical pharmacology and recommended therapeutic use. Drugs. 1999;57(6):855-870.  
  56. Wolfe MM, Sachs G. Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress ulcer prophylaxis. Gastroenterology. 2000;118(2 Suppl 1):S9-S31.  
  57. Shin JM, Sachs G. Pharmacology of proton pump inhibitors. Curr Gastroenterol Rep. 2008;10(6):528-534. 
  58. Tonini M, Cipollina L, Poluzzi E, Crema F, Corazza GR, De Ponti F. Review article: clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics. Aliment Pharmacol Ther. 2004;19(4):379-390.  
  59. Rao AS, Camilleri M. Review article: metoclopramide and tardive dyskinesia. Aliment Pharmacol Ther. 2010;31(1):11-19.  
  60. Ozdal T, Capanoglu E, Altay F. A review on protein-polyphenol interactions and their effects on food quality and human health. Food Funct. 2013;4(11):1582-1593.  
  61. Tack J, Camilleri M, Chang L, Chey WD, Galligan JJ, Lacy BE, et al. Systematic review: cardiovascular safety profile of 5-HT4 agonists developed for gastrointestinal disorders. Aliment Pharmacol Ther. 2012;35(7):745-767.  
  62. Hirschowitz BI, Worthington J, Mohnen J. Vitamin B12 deficiency in hypersecretors during long-term omeprazole therapy. Aliment Pharmacol Ther. 2008;27(11):1110-1121.  
  63. Charlot M, Ahlehoff O, Norgaard ML, Jørgensen CH, Sørensen R, Abildstrøm SZ, et al. Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study. Ann Intern Med. 2010;153(6):378-386.  
  64. Gomm W, von Holt K, Thomé F, Broich K, Maier W, Fink A, et al. Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis. JAMA Neurol. 2016;73(4):410-416.  
  65. Tai SY, Chien CY, Wu DC, Lin KD, Ho BL, Chang YH, et al. Risk of dementia from proton pump inhibitor use in Asian population: a nationwide cohort study in Taiwan. PLoS One. 2017;12(2):e0171006.  
  66. Bravo JA, Forsythe P, Chew MV, Escaravage E, Savignac HM, Dinan TG, et al. Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. Proc Natl Acad Sci U S A. 2011;108(38):16050-16055.  
  67. Fuchs KH, DeMeester TR, Albertucci M. Specificity and sensitivity of objective diagnosis of gastroesophageal reflux disease. Surgery. 1987;102(4):575-580.  
  68. den Elzen WP, Groeneveld Y, de Ruijter W, Souverijn JH, le Cessie S, Assendelft WJ, et al. Long-term use of proton pump inhibitors and vitamin B12 status in elderly individuals. Aliment Pharmacol Ther. 2008;27(6):491-497.  
  69. Spechler SJ, Souza RF. Barrett's esophagus. N Engl J Med. 2014;371(9):836-845. 
  70. Hungin AP, Rubin G, O'Flanagan H. Factors influencing compliance in long-term proton pump inhibitor therapy in general practice. Br J Gen Pract. 1999;49(443):463-464.  
  71. Rao AS, Camilleri M. Review article: metoclopramide and tardive dyskinesia. Aliment Pharmacol Ther. 2010;31(1):11-19.  
  72. Shargel L, Wu-Pong S, Yu ABC. Applied Biopharmaceutics & Pharmacokinetics. 6th ed. New York: McGraw-Hill Medical; 2012.  
  73. Zhou SF, Xue CC, Yu XQ, Li C, Wang G. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit. 2007;29(6):687-710.  
  74. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications. JAMA. 2002;287(17):2215-2220.  
  75. Jones DS, Hofmann L, Quinn S. 21st Century Medicine: A New Model for Medical Education and Practice. Gig Harbor: Institute for Functional Medicine; 2009.  
  76. Burdock GA, Carabin IG. Generally recognized as safe (GRAS): history and description. Toxicol Lett. 2004;150(1):3-18.  
  77. Strom BL, Kimmel SE, Hennessy S. Pharmacoepidemiology. 5th ed. West Sussex: Wiley-Blackwell; 2012. 
  78. Niklasson A, Lindberg L, Simrén M, Lindberg B, Björnsson E. Dyspeptic symptom development after discontinuation of a proton pump inhibitor: a double-blind placebo-controlled trial. Am J Gastroenterol. 2010;105(7):1531-1537.  
  79. Deters A, Zippel J, Hellenbrand N, Pappai D, Possemeyer C, Hensel A. Aqueous extracts and polysaccharides from Marshmallow roots (Althea officinalis L.): cellular internalization and stimulation of cell physiology of human epithelial cells in vitro. J Ethnopharmacol. 2010;127(1):62-69.  
  80. Raut JS, Karuppayil SM. A status review on the medicinal properties of essential oils. Ind Crops Prod. 2014;62:250-264.